As demonstrated by the experiment in Figure 5E, addition of the W6/32 antibody was sufficient to reduce lysis of CLL targets by 73% (p = 0.00003) and lysis of the alloantigen CD8+ control by 100% (p = 0.00006). This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.